AMGEN INC
For the period ended Mar 31, 2025. Filed May 2, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 2, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
DEFINED TERMS AND PRODUCTSii
Defined Terms and Products
Defined terms
We use several terms in this Form 10-Q, including but not limited to those that are finance, regulation and disease-state related, as well as names of other companies, which are given below.
| Term | Description |
|---|---|
| 340B Program | Federal 340B Drug Pricing Program |
| AOCI | accumulated other comprehensive income (loss) |
| AstraZeneca | AstraZeneca plc |
| BeiGene | BeiGene, Ltd. |
| BPCIA | Biologics Price Competition and Innovation Act of 2009 |
| CMS | Centers for Medicare & Medicaid Services |
| EMA | European Medicines Agency |
| EPS | earnings per share |
| EU | European Union |
| FDA | U.S. Food and Drug Administration |
| Fitch | Fitch Ratings, Inc. |
| FTC | Federal Trade Commission |
| GAAP | U.S. generally accepted accounting principles |
| HHS | U.S. Department of Health and Human Services |
| Horizon | Horizon Therapeutics plc |
| IPR&D | in-process research and development |
| IRA | Inflation Reduction Act of 2022 |
| IRS | Internal Revenue Service |
| MD&A | management’s discussion and analysis |
| Moody’s | Moody’s Investors Service, Inc. |
| Neumora | Neumora Therapeutics, Inc. |
| NIH | National Institutes of Health |
| OECD | Organisation for Economic Co-operation and Development |
| PBM | pharmacy benefit manager |
| PDAB | Prescription Drug Affordability Board |
| R&D | research and development |
| RANKL | receptor activator of nuclear factor kappa-B ligand |
| RAR | Revenue Agent Report |
| ROW | rest of world |
| S&P | Standard & Poor’s Financial Services LLC |
| SEC | U.S. Securities and Exchange Commission |
| SG&A | selling, general and administrative |
| SOFR | Secured Overnight Financing Rate |
| U.S. Treasury | U.S. Department of the Treasury |
| UTB | unrecognized tax benefit |
ii
Products
The brand names of our products, our delivery devices and certain of our product candidates and their associated generic names are given below.
| Term | Description |
|---|---|
| ACTIMMUNE | ACTIMMUNE® (interferon gamma-1b) |
| Aimovig | Aimovig® (erenumab-aooe) |
| AMJEVITA/AMGEVITA | AMJEVITA® (adalimumab-atto)/AMGEVITA™ (adalimumab) |
| Aranesp | Aranesp® (darbepoetin alfa) |
| AVSOLA | AVSOLA® (infliximab-axxq) |
| BEKEMV | BEKEMV™ (eculizumab) |
| BLINCYTO | BLINCYTO® (blinatumomab) |
| BUPHENYL | BUPHENYL® (sodium phenylbutyrate) |
| Corlanor | Corlanor® (ivabradine) |
| ENBREL | Enbrel® (etanercept) |
| EPOGEN | EPOGEN® (epoetin alfa) |
| EVENITY | EVENITY® (romosozumab-aqqg) |
| IMDELLTRA/IMDYLLTRA | IMDELLTRA® (tarlatamab-dlle)/IMDYLLTRA™ (tarlatamab) |
| IMLYGIC | IMLYGIC® (talimogene laherparepvec) |
| KANJINTI | KANJINTI® (trastuzumab-anns) |
| KRYSTEXXA | KRYSTEXXA® (pegloticase) |
| KYPROLIS | KYPROLIS® (carfilzomib) |
| LUMAKRAS/LUMYKRAS | LUMAKRAS®/LUMYKRAS™ (sotorasib) |
| MVASI | MVASI® (bevacizumab-awwb) |
| Neulasta | Neulasta® (pegfilgrastim) |
| NEUPOGEN | NEUPOGEN® (filgrastim) |
| Nplate | Nplate® (romiplostim) |
| Otezla | Otezla® (apremilast) |
| Parsabiv | Parsabiv® (etelcalcetide) |
| PAVBLU | PAVBLU® (aflibercept-ayyh) |
| PENNSAID | PENNSAID® (diclofenac sodium topical solution) 2% |
| PROCYSBI | PROCYSBI® (cysteamine bitartrate) |
| Prolia | Prolia® (denosumab) |
| QUINSAIR | QUINSAIR® (levofloxacin) |
| RAVICTI | RAVICTI® (glycerol phenylbutyrate) |
| RAYOS | RAYOS® (prednisone) |
| Repatha | Repatha® (evolocumab) |
| RIABNI | RIABNI® (rituximab-arrx) |
| Sensipar/Mimpara | Sensipar®/Mimpara™ (cinacalcet) |
| TAVNEOS | TAVNEOS® (avacopan) |
| TEPEZZA | TEPEZZA® (teprotumumab-trbw) |
| TEZSPIRE | TEZSPIRE® (tezepelumab-ekko) |
| UPLIZNA | UPLIZNA® (inebilizumab-cdon) |
| Vectibix | Vectibix® (panitumumab) |
| WEZLANA/WEZENLA | WEZLANA™ (ustekinumab-auub)/WEZENLA™ (ustekinumab) |
| XGEVA | XGEVA® (denosumab) |
iii
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.